Skip to content

Study · Not a test of the peptide alone · 2018

3 results

Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.

Takayanagi R, Uchida T, Kimura K, Yamada Y

Biological & pharmaceutical bulletin1 Jan 2018Cited by 4 (Europe PMC)

PMID29386477 (opens in a new tab)DOI10.1248/bpb.b17-00237 (opens in a new tab)PepBankPUB-29386477
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01Computer modelNot a test of Liraglutide aloneIn silicoActivity measurement

    In a theoretical analysis, GLP-1 receptor agonists (liraglutide, exenatide, lixisenatide) produced their clinical effect at a relatively low receptor binding occupancy of 1.1-10.7% at a usual dose.

    In plain wordsIn a computer-based analysis, GLP-1 receptor drugs as a group, including liraglutide, worked at a low level of receptor occupancy.

    Peptide
    Liraglutide
    Outcome
    Not applicableGLP-1 receptor binding occupancy at usual dose
    Study

    n: not reported in source

    Theoretical receptor-occupancy analysis
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    Binding occupancy (Φ)
    1.1 to 10.7%
    GLP-1 receptor agonists at usual dose

    Source sentences

    Summary
    The present results showed that GLP-1 receptor agonists produced their clinical effect at a relatively low level of Φ (1.1-10.7%) at a usual dose.
    2 context sentences
    Summary · context
    Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide, lixisenatide) have recently been used as anti-diabetes drugs.
    Summary · context
    We examined relationships of the binding occupancy of GLP-1 receptors (Φ) and their clinical efficacy after administration of GLP-1 receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02Computer modelNot a test of Liraglutide aloneIn silicoEfficacy outcome

    In a theoretical analysis, the predicted HbA1c reduction with GLP-1 receptor agonists (including liraglutide) was higher than with DPP-4 inhibitors.

    In plain wordsIn a computer-based analysis, GLP-1 receptor drugs as a group, including liraglutide, were predicted to lower HbA1c more than DPP-4 inhibitors.

    Peptide
    Liraglutide
    Outcome
    DecreasePredicted HbA1c reduction, GLP-1 receptor agonists versus DPP-4 inhibitors
    Study

    n: not reported in source

    Theoretical receptor-occupancy analysis
    Comparator
    DPP-4 inhibitors
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Accordingly, the predicted value for hemoglobin A1c (HbA1c) reduction after administration of the GLP-1 receptor agonists was higher than that of DPP-4 inhibitors.
    2 context sentences
    Summary · context
    Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide, lixisenatide) have recently been used as anti-diabetes drugs.
    Summary · context
    We examined relationships of the binding occupancy of GLP-1 receptors (Φ) and their clinical efficacy after administration of GLP-1 receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03Computer modelNot a test of Liraglutide aloneIn silicoActivity measurement

    In a theoretical analysis, the receptor occupancy value of DPP-4 inhibitors (0.83-1.3%) was at the lower end of, or lower than, that of GLP-1 receptor agonists (including liraglutide) at a usual dose.

    In plain wordsIn a computer-based analysis, DPP-4 inhibitors reached the same or lower receptor occupancy than GLP-1 receptor drugs such as liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableBinding occupancy of DPP-4 inhibitors versus GLP-1 receptor agonists
    Study

    n: not reported in source

    Theoretical receptor-occupancy analysis
    Comparator
    DPP-4 inhibitors
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    Binding occupancy (Φ), DPP-4 inhibitors
    0.83 to 1.3%
    DPP-4 inhibitors

    Source sentences

    Summary
    It was also revealed that the Φ value of DPP-4 inhibitors (0.83-1.3%) was at the lower end or lower than that of GLP-1 receptor agonists at a usual dose.
    2 context sentences
    Summary · context
    Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide, lixisenatide) have recently been used as anti-diabetes drugs.
    Summary · context
    We examined relationships of the binding occupancy of GLP-1 receptors (Φ) and their clinical efficacy after administration of GLP-1 receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.